Ang Song Peng, Chia Jia Ee, Iglesias Jose, Usman Muhammed Haris, Krittanawong Chayakrit
Department of Medicine, Rutgers Health/Community Medical Center, Toms River, NJ, USA.
Department of Medicine, Texas Tech University Health Science Center, El Paso, TX, USA.
Curr Cardiol Rep. 2025 Jan 4;27(1):2. doi: 10.1007/s11886-024-02163-x.
This review assesses the outcomes of coronary interventions in patients with liver cirrhosis and coronary artery disease (CAD), focusing on the clinical challenges posed by cirrhosis-related hemodynamic and coagulopathic changes. It highlights essential considerations for managing these patients, who have an increased risk of adverse events during coronary procedures.
Recent studies have shown that patients with liver cirrhosis undergoing PCI experience significantly higher mortality rates compared to non-cirrhotic patients, particularly in the context of STEMI and NSTEMI. Coagulopathy and thrombocytopenia increase the risk of bleeding and vascular complications during interventions. Radial access has been suggested as a safer alternative to femoral access in these patients due to reduced bleeding complications. Additionally, contrast-induced nephropathy (CIN) is a prevalent risk, with cirrhotic patients demonstrating higher rates of acute kidney injury post-PCI. Preventive strategies such as minimizing contrast exposure and utilizing intravascular ultrasound (IVUS) are recommended. Managing CAD in cirrhotic patients requires careful consideration of their unique pathophysiological state. Higher in-hospital mortality, bleeding risks, and vascular complications necessitate tailored procedural strategies, such as radial access and contrast minimization. The balance between thrombotic and bleeding risks is critical in decision-making, with IVUS and hydration strategies being promising approaches. Further research is required to optimize treatment protocols and improve long-term outcomes for this high-risk population.
本综述评估肝硬化合并冠状动脉疾病(CAD)患者的冠状动脉介入治疗结果,重点关注肝硬化相关血流动力学和凝血功能改变所带来的临床挑战。它强调了管理这些患者的重要注意事项,这些患者在冠状动脉手术期间发生不良事件的风险增加。
最近的研究表明,与非肝硬化患者相比,接受经皮冠状动脉介入治疗(PCI)的肝硬化患者死亡率显著更高,尤其是在ST段抬高型心肌梗死(STEMI)和非ST段抬高型心肌梗死(NSTEMI)的情况下。凝血功能障碍和血小板减少会增加干预期间出血和血管并发症的风险。由于出血并发症减少,桡动脉穿刺被认为是这些患者比股动脉穿刺更安全的选择。此外,造影剂肾病(CIN)是一种常见风险,肝硬化患者PCI术后急性肾损伤发生率更高。建议采取如减少造影剂暴露和使用血管内超声(IVUS)等预防策略。管理肝硬化患者的CAD需要仔细考虑其独特的病理生理状态。较高的住院死亡率、出血风险和血管并发症需要制定个性化的手术策略,如桡动脉穿刺和减少造影剂使用。在决策过程中,血栓形成和出血风险之间的平衡至关重要,IVUS和水化策略是有前景的方法。需要进一步研究以优化治疗方案并改善这一高危人群的长期预后。